Journal · Updated 2026-08-11

Henry Meds Review 2026: The $179 Flat Benchmark, Audited

By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify

The structure: what flat actually means here

Henry's model is the market's simplest sentence: one price, both molecules, every dose, everything included, leave when you want. No membership fee, no consultation charge, no dose-based escalation — the structure that makes it immune to four of the five teaser mechanisms (its ad and its checkout say the same number), and the structure our database rewards with a clean, rankable row. The forty-one-state footprint is the broadest published list among the flat-rate programs, and its nine exclusions are stated rather than discovered at intake. An oral tirzepatide tablet option exists at higher monthly prices for the injection-averse. Cancellation is standard month-to-month. For a buyer who wants the least homework per dollar in the compounded market, this is the shape that requires it.

The gaps, stated plainly

Three. First, the pharmacy is not named — "partner 503A" is the entire public disclosure, which means the fifteen-minute vetting process can't start until you extract the name at intake; ask, in writing, and treat refusal as an answer. Second, no brand path: a patient who later wants Wegovy or Zepbound leaves Henry rather than switching within it — a real limitation as brand floors fall. Third, a corrected history worth knowing: our database briefly carried Henry tirzepatide at $349 from a stale source before two independent 2026 captures established the $179 flat figure — the correction is logged, dated, in our corrections log, and it's why the row reads "reported" rather than "verified" pending our own checkout capture. None of the three is disqualifying; all three belong in the decision.

Verdict, against the field

On tirzepatide month-to-month, Henry at one seventy-nine sits ten dollars behind NexLife's promotional one sixty-nine and ties bmiMD — with NexLife's edge expiring August 31 unless locked, at which point Henry's flat one seventy-nine likely resumes co-leading the no-commitment tier against NexLife's two-fifteen standard card. On semaglutide it's mid-pack: bmiMD's one twenty-nine, HealthRX's one thirty-three, and NexLife's one thirty-nine all undercut it month-to-month, and the ninety-nine-dollar committed plans undercut it further. On simplicity it leads outright. The honest recommendation shape: Henry is the strongest default for a tirzepatide buyer who values month-to-month freedom, stated exclusions, and zero pricing homework — provided the pharmacy-name question gets asked, and answered, before the first charge.

This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.